Nurix Therapeutics Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Nurix Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $31. The average 1-year stock price forecast is 82.89% higher than the current stock price, while the lowest is $23 (+35.69%) and the highest is $45 (+165.49%).

Price Target: $31 (+82.89%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$23	$31	$31	$45
Change	+35.69%	+82.89%	+82.89%	+165.49%

Analyst Ratings

The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	12	12	12	12	12	10
Buy	5	5	5	5	5	5
Hold	0	0	0	0	0	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	17	17	17	17	17	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tessa Romero J.P. Morgan	J.P. Morgan	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 12, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $32	Buy	Reiterates	$32	+88.79%	Jun 10, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Buy Maintains $15 → $36	Buy	Maintains	$15 → $36	+112.39%	Jun 9, 2026
Jeet Mukherjee BTIG	BTIG	Buy Maintains $32	Buy	Maintains	$32	+88.79%	Jun 9, 2026
Gregory Renza Truist Financial	Truist Financial	Buy Reiterates $30 → $32	Buy	Reiterates	$30 → $32	+88.79%	Jun 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

143.52M

from 83.98M

70.90%

from 83.98M

Revenue Next Year

82.28M

from 143.52M

-42.67%

from 143.52M

EPS This Year

-2.35

from -3.05

EPS Next Year

-2.68

from -2.35

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Nov 30, 2021	Nov 30, 2022	Nov 30, 2023	Nov 30, 2024	Nov 30, 2025	Nov 30, 2026
Revenue	29.75M	38.63M	76.99M	54.55M	83.98M	143.52M
Revenue Growth	66.95%	29.84%	99.31%	-29.15%	53.95%	70.90%
Gross Profit	-86.68M	-145.87M	-112.16M	-167.08M	-232.92M	143.52M
Gross Margin	-291.37%	-377.64%	-145.69%	-306.30%	-277.36%	100.00%
Operating Income	-117.89M	-183.87M	-155.06M	-213.03M	-285.67M	-235.59M
Net Income	-117.19M	-180.36M	-143.95M	-193.57M	-264.46M	-217.03M
EPS	-	-	-	-	-3.05	-2.35
Free Cash Flow	-37.70M	-79.42M	-41.93M	-85.90M	-143.99M	-270.67M
No. Analysts	-	-	-	-	-	16

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	821.3M
Avg	143.5M
Low	14.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	878.0%
Avg	70.9%
Low	-82.7%

EPS Forecast

EPS	2026	2027	2028
High	3.70
Avg	-2.35
Low	-3.28

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-